Selected articles
Articles for label Študentová Hana are displayed.. Show all articles
Niraparib
04/2021 MUDr. Aleš Langer; MUDr. Hana Študentová, Ph.D.
Niraparib is younger member of PARP inhibitors family. Some PARP inhibitors are used in treatment of ovarian carcinoma routinely. This carcinoma is the most lethal of all Gynecological carcinomas. Incidence of this cancer is slightly decreasing, but it is still one of the most common cancers leading to death in women worldwide. The ovarian carcinomas are often diagnosed in an advanced clinical stage 3 or 4. Ovarian cancer is usually sensitive to platinum and taxane based chemotherapy, but treatment resistance and relapses develop throughout the disease course. Niraparib works as a maintenance therapy in a recurrent ovarian carcinoma. Niraparib provides the best results in BRCA1/2 mutated patients.
ENTIRE ARTICLE
Niraparib is younger member of PARP inhibitors family. Some PARP inhibitors are used in treatment of ovarian carcinoma routinely. This carcinoma is the most lethal of all Gynecological carcinomas. Incidence of this cancer is slightly decreasing, but it is still one of the most common cancers leading to death in women worldwide. The ovarian carcinomas are often diagnosed in an advanced clinical stage 3 or 4. Ovarian cancer is usually sensitive to platinum and taxane based chemotherapy, but treatment resistance and relapses develop throughout the disease course. Niraparib works as a maintenance therapy in a recurrent ovarian carcinoma. Niraparib provides the best results in BRCA1/2 mutated patients.
Prostate cancer – sequencing of systemic treatment of systemic disease – case report
02/2021 MUDr. Nikol Rušarová; MUDr. Hana Študentová, Ph.D.
Prostate cancer is one of the most common cancers in men worldwide. Many patients have and advanced disease despite of early diagnosis. Finding the optimal treatment sequencing in advanced prostate cancer is currently one of the most common question.
ENTIRE ARTICLE
Prostate cancer is one of the most common cancers in men worldwide. Many patients have and advanced disease despite of early diagnosis. Finding the optimal treatment sequencing in advanced prostate cancer is currently one of the most common question.
Where is the right place for immunotherapy for advanced kidney cancer?
02/2018 MUDr. Hana Študentová, Ph.D.
Targeted therapy of renal cell carcinoma has evolved enormously during past ten years. Inhibitors of angiogenesis have dominated exclusively in the treatment algorithm until recently, when immunotherapy has become a potential rival. Immunotherapy has been going through a revival due to a different and attractive mechanism of fight against cancer. New molecules have emerged to show efficacy with a regard of response rate, improving survival outcome, however, the key question remains unanswered - what is the optimal sequence of therapy including immunotherapy in the treatment of renal cell carcinoma?
ENTIRE ARTICLE
Targeted therapy of renal cell carcinoma has evolved enormously during past ten years. Inhibitors of angiogenesis have dominated exclusively in the treatment algorithm until recently, when immunotherapy has become a potential rival. Immunotherapy has been going through a revival due to a different and attractive mechanism of fight against cancer. New molecules have emerged to show efficacy with a regard of response rate, improving survival outcome, however, the key question remains unanswered - what is the optimal sequence of therapy including immunotherapy in the treatment of renal cell carcinoma?